Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $1.08 in the prior trading day, Rani Therapeutics Holdings Inc (NASDAQ: RANI) closed at $0.84, down -22.41%. In other words, the price has decreased by -$22.41 from its previous closing price. On the day, 0.68 million shares were traded.
Ratios:
Our goal is to gain a better understanding of RANI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.50. In the meantime, Its Debt-to-Equity ratio is 14.93 whereas as Long-Term Debt/Eq ratio is at 6.66.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Oppenheimer on August 02, 2024, initiated with a Outperform rating and assigned the stock a target price of $17.
On June 14, 2024, Maxim Group started tracking the stock assigning a Buy rating and target price of $15.
On June 13, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $10.Rodman & Renshaw initiated its Buy rating on June 13, 2024, with a $10 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 13 ’24 when McKinley Kate bought 17,960 shares for $1.67 per share. The transaction valued at 29,993 led to the insider holds 17,960 shares of the business.
Imran Talat bought 10,296 shares of RANI for $19,974 on Dec 09 ’24. The Chief Executive Officer now owns 494,751 shares after completing the transaction at $1.94 per share. On Oct 15 ’24, another insider, South Cone Investments Limited, who serves as the 10% Owner of the company, sold 3,829,360 shares for $2.65 each. As a result, the insider received 10,141,674 and left with 8,302,194 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 46.82 while its Price-to-Book (P/B) ratio in mrq is 14.06.
Stock Price History:
Over the past 52 weeks, RANI has reached a high of $7.88, while it has fallen to a 52-week low of $1.02. The 50-Day Moving Average of the stock is -35.71%, while the 200-Day Moving Average is calculated to be -56.51%.
Shares Statistics:
A total of 33.43M shares are outstanding, with a floating share count of 22.79M. Insiders hold about 32.12% of the company’s shares, while institutions hold 8.28% stake in the company.
Earnings Estimates
Rani Therapeutics Holdings Inc (RANI) is presently subject to a detailed evaluation by 1.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.24 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$0.74 and -$0.96 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is -$0.71, with 3.0 analysts recommending between -$0.47 and -$1.01.
